Boehringer Ingelheim increases awareness of health with the micro enterprise project 'Elephants' in South India

Boehringer IngelheimBoehringer Ingelheim announced the start of a new self-help project in India to increase awareness of hygiene and health. On the occasion of the Global Handwashing Day 2018, October 15 the company would like to draw attention to the hygienic conditions in the impoverished regions around the world. Many diseases are spread by not washing hands, as a result of lack of knowledge, very limited access to hygiene products, awareness and missing access to clean water: According to UNICEF, diarrhea remains the second largest cause of mortality for children aged under-five globally. Every year, 1.4 million children die from diarrheal diseases due to a lack of safe water, bad sanitation and basic hygiene.

The Boehringer Ingelheim initiative called ‘Elephants’ was launched end of September 2018 in Coimbatore within the Indian state of Tamil Nadu with a training course for 60 village inhabitants on soap production. The objective is to enable a healthier living in the villages and creating simultaneously an income source for the communities by self-managed soap micro-enterprises. Additionally, the project aims to create business knowledge and logistics skills amongst the participants so that they will be able to independently market their homemade soaps in future. Another core task of this initiative is to increase awareness of infections with communicable diseases due to bad hygiene. The 'Elephants' project is run by Boehringer Ingelheim employees who volunteered to engage in company-sponsored projects in India through the company's initiative Making More Health.

"We know from the western world that there is no health without wealth. This experience seems unknown, unmet or unsolved in our project area. In order to solve this problem we have to combine health with solutions that create an income," explains Manolis Mitakis, Pharmacist and Head of Communications & Public Affairs of the Greek subsidiary of Boehringer Ingelheim, who travelled to India, involved in the Making More Health Executive in Residence Program.

The Boehringer Ingelheim long-term and global initiative Making More Health (MMH) aims to create a healthier world for individuals, communities and families. By supporting social entrepreneurs and social entrepreneurial thinking, MMH is looking for innovative solutions, which create social impact. Together with the local partner-NGO, the Karl Kübel Institute for Development Education and the German federal state Hessen toilets are built or renovated to increase hygiene among schoolchildren in the chosen territory in Tamil Nadu/ India. Education and awareness programs on hygiene help a lot that children can visit schools at a regular basis. However, awareness is only the first step to prevent diseases. The second step is to make sure that the knowledge leads to the right hygienic behavior and here soap can play a major role.

"Our MMH activities in India started in 2015 in close collaboration with local stakeholders. That's why we co- create with others, build kindergarten buildings and train kindergarten teachers on health awareness in the rural villages, provide toilets in schools and contribute actively to a hygiene campaign of one of our social entrepreneurs in our network. A two year health awareness program for tribal people including various health topics and digital trainings as well as safety trainings for daily life are also part of our activities. With teaching people skills and enabling them to create their own income we do a next step. We run regularly leadership weeks for our managers in our project area, close to Coimbatore - and we learn a lot: because understanding and talking to the local communities and organizations is important to develop solutions that are meeting the real needs and which are accepted," says Manuela Pastore, global lead of Making More Health.

About Boehringer Ingelheim

Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 17.0 per cent of net sales.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.

Most Popular Now

Preventing tumor metastasis

Researchers at the Paul Scherrer Institute, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the dev...

A new drug could revolutionize the treatment of ne…

The international team of scientists from Gero Discovery LLC, the Institute of Biomedical Research of Salamanca, and Nanosyn, Inc. has found a potential drug that may pre...

Interactions discovered in cells insulating nerve …

Schwann cells form a protective sheath around nerve fibres and ensure that nerve impulses are transmitted rapidly. If these cells are missing or damaged, severe neurologi...

Breast cancer can form 'sleeper cells' after drug …

Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life years after initial treatment. These are the early...

Anniversary of the pivotal RE-LY® trial marks a de…

Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, heal...

Experimental validation confirms the ability of ar…

Insilico Medicine, a global leader in artificial intelligence for drug discovery, announced the publication of a paper titled, "Deep learning enables rapid identification...

AstraZeneca agrees to buy US FDA Priority Review V…

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsid...

Boehringer Ingelheim eExpands KRAS cancer program …

Boehringer Ingelheim and Lupin Limited (Lupin) announced a licensing, development and commercialization agreement for Lupin's MEK inhibitor compound (LNP3794) as a potent...

Pfizer invests half billion dollars to advance sta…

Pfizer announced an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina...

FDA grants Fast Track designation for Farxiga in c…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the ...

The Pfizer Foundation invests in 20 organizations …

The Pfizer Foundation announced 20 grants* to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to...

Tagrisso approved in China as a 1st-line treatment…

AstraZeneca today announced that it has received marketing authorisation from China's National Medical Products Administration (NMPA) for Tagrisso (osimertinib) as a 1st-...